Difference between revisions of "Editorial Board"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 1: Line 1:
−
Please feel free to contact us with any questions or inquiries, at the email addresses below.
+
Please feel free to contact us with any questions or inquiries, at [mailto:[email protected] [email protected]].
  
 
=Editor-in-Chief=
 
=Editor-in-Chief=
−
{| border="1" style="text-align:center;"
+
{| border="1" style="text-align:center; width: 60%;"
 
|-
 
|-
−
|[[File:PeterYang.jpg|thumb|upright=0.4|center]]
+
|style="background-color:#F0F0F0; width: 42%;"|[[File:PeterYang.jpg|thumb|upright=0.4|center]]
−
|<big>[[User:PeterYang|Peter C. Yang, MD]]<br>Boston, MA</big><br>[mailto:[email protected] [email protected]]<br>Twitter: [https://twitter.com/Hem_Onc Hem_Onc]
+
|<big>[[User:PeterYang|Peter C. Yang, MD]]<br>Boston, MA</big><br>Twitter: [https://twitter.com/Hem_Onc Hem_Onc]
 
|-
 
|-
 
|}
 
|}
  
 
=Deputy Editor=
 
=Deputy Editor=
−
{| border="1" style="text-align:center;"
+
{| border="1" style="text-align:center; width: 60%;"
 
|-
 
|-
−
|[[File:Warner Jeremy2 compact.jpg|thumb|upright=0.4|center]]
+
|style="background-color:#F0F0F0; width: 42%;"|[[File:Warner Jeremy2 compact.jpg|thumb|upright=0.4|center]]
−
|<big>[[User:Jwarner|Jeremy L. Warner, MD, MS]]<br>Nashville, TN</big><br>[mailto:[email protected] [email protected]]<br>Twitter: [https://twitter.com/Hemoncwarner Hemoncwarner]<br>[https://www.linkedin.com/in/jeremy-warner-39001512/ LinkedIn]
+
|<big>[[User:Jwarner|Jeremy L. Warner, MD, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/Hemoncwarner Hemoncwarner]<br>[https://www.linkedin.com/in/jeremy-warner-39001512/ LinkedIn]
 
|-
 
|-
 
|}
 
|}
Line 21: Line 21:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Dermatologic Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Dermatologic Oncology'''
 
|-
 
|-
−
|rowspan=4 style="background-color:#F0F0F0"|[[File:Bethbuchbinder.jpg|thumb|upright=0.4|center]]
+
|rowspan=4 style="background-color:#F0F0F0; width:25%;"|[[File:Bethbuchbinder.jpg|thumb|upright=0.4|center]]
−
|rowspan=4|<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn]
+
|rowspan=4 style="width:35%"|<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn]
−
|style="width: 25%; background-color:#deebf7"|[[Melanoma]]
+
|style="background-color:#deebf7"|[[Melanoma]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Merkel cell carcinoma]]
+
|style="background-color:#deebf7"|[[Merkel cell carcinoma]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Basal cell and squamous cell skin cancer]]
+
|style="background-color:#deebf7"|[[Basal cell and squamous cell skin cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Cutaneous T-cell lymphoma]]
+
|style="background-color:#deebf7"|[[Cutaneous T-cell lymphoma]]
 
|-
 
|-
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gastrointestinal Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gastrointestinal Oncology'''
Line 35: Line 35:
 
|rowspan=8 style="background-color:#F0F0F0"|Coming soon
 
|rowspan=8 style="background-color:#F0F0F0"|Coming soon
 
|rowspan=8|<big>Neeta Venepalli, MD<br>Chicago, IL</big>
 
|rowspan=8|<big>Neeta Venepalli, MD<br>Chicago, IL</big>
−
|style="width: 25%; background-color:#deebf7"|[[Anal cancer]]
+
|style="background-color:#deebf7"|[[Anal cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Colon cancer]]
+
|style="background-color:#deebf7"|[[Colon cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]]
+
|style="background-color:#deebf7"|[[Esophageal cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Gastric cancer]]
+
|style="background-color:#deebf7"|[[Gastric cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
+
|style="background-color:#deebf7"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Hepatobiliary cancer]]
+
|style="background-color:#deebf7"|[[Hepatobiliary cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Pancreatic cancer]]  
+
|style="background-color:#deebf7"|[[Pancreatic cancer]]  
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Rectal cancer]]
+
|style="background-color:#deebf7"|[[Rectal cancer]]
 
|-
 
|-
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Genitourinary Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Genitourinary Oncology'''
Line 55: Line 55:
 
|rowspan=5 style="background-color:#F0F0F0"|Coming soon
 
|rowspan=5 style="background-color:#F0F0F0"|Coming soon
 
|rowspan=5|<big>Aymen Elfiky, MD, MSc, MBA<br>Boston, MA</big><br>[https://www.linkedin.com/in/aymen-elfiky-15420873/ LinkedIn]
 
|rowspan=5|<big>Aymen Elfiky, MD, MSc, MBA<br>Boston, MA</big><br>[https://www.linkedin.com/in/aymen-elfiky-15420873/ LinkedIn]
−
|style="width: 25%; background-color:#deebf7"|[[Bladder cancer]]
+
|style="background-color:#deebf7"|[[Bladder cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Penile cancer]]
+
|style="background-color:#deebf7"|[[Penile cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Prostate cancer]]
+
|style="background-color:#deebf7"|[[Prostate cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Renal cancer]]
+
|style="background-color:#deebf7"|[[Renal cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Testicular cancer]]
+
|style="background-color:#deebf7"|[[Testicular cancer]]
 
|-
 
|-
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gynecologic Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gynecologic Oncology'''
Line 69: Line 69:
 
|rowspan=4 style="background-color:#F0F0F0"|[[File:BrandonSeagle.jpg|thumb|upright=0.4|center]]
 
|rowspan=4 style="background-color:#F0F0F0"|[[File:BrandonSeagle.jpg|thumb|upright=0.4|center]]
 
|rowspan=4|<big>[[User:Blseagle|Brandon L. Seagle, MD, MS]]<br>Chicago, IL</big>
 
|rowspan=4|<big>[[User:Blseagle|Brandon L. Seagle, MD, MS]]<br>Chicago, IL</big>
−
|style="width: 25%; background-color:#deebf7"|[[Cervical cancer]]
+
|style="background-color:#deebf7"|[[Cervical cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Germ cell tumors]]
+
|style="background-color:#deebf7"|[[Germ cell tumors]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Ovarian cancer]]
+
|style="background-color:#deebf7"|[[Ovarian cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Uterine cancer]]
+
|style="background-color:#deebf7"|[[Uterine cancer]]
 
|-
 
|-
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Neuro-Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Neuro-Oncology'''
Line 81: Line 81:
 
|rowspan=4 style="background-color:#F0F0F0"|[[File:SeemaNagpal.jpg|thumb|upright=0.4|center]]
 
|rowspan=4 style="background-color:#F0F0F0"|[[File:SeemaNagpal.jpg|thumb|upright=0.4|center]]
 
|rowspan=4|<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Palo Alto, CA</big>
 
|rowspan=4|<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Palo Alto, CA</big>
−
|style="width: 25%; background-color:#deebf7"|[[Central nervous system (CNS) cancer]]
+
|style="background-color:#deebf7"|[[Central nervous system (CNS) cancer]]
 
|-
 
|-
 
|style="background-color:#fee0d2"|[[CNS leukemia]]
 
|style="background-color:#fee0d2"|[[CNS leukemia]]
Line 87: Line 87:
 
|style="background-color:#fee0d2"|[[CNS lymphoma]]
 
|style="background-color:#fee0d2"|[[CNS lymphoma]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Glioblastoma]]
+
|style="background-color:#deebf7"|[[Glioblastoma]]
 
|-
 
|-
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Sarcoma'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Sarcoma'''
Line 93: Line 93:
 
|rowspan=4 style="background-color:#F0F0F0"|Coming soon
 
|rowspan=4 style="background-color:#F0F0F0"|Coming soon
 
|rowspan=4|<big>James L. Chen, MD, MS<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn]
 
|rowspan=4|<big>James L. Chen, MD, MS<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn]
−
|style="width: 25%; background-color:#deebf7"|[[Ewing's sarcoma]]
+
|style="background-color:#deebf7"|[[Ewing's sarcoma]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Gastrointestinal stromal tumor]]
+
|style="background-color:#deebf7"|[[Gastrointestinal stromal tumor]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Osteosarcoma]]
+
|style="background-color:#deebf7"|[[Osteosarcoma]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Sarcoma|Sarcoma (other types)]]
+
|style="background-color:#deebf7"|[[Sarcoma|Sarcoma (other types)]]
 
|-
 
|-
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Thoracic Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Thoracic Oncology'''
Line 105: Line 105:
 
|rowspan=5 style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|thumb|upright=0.4|center]]
 
|rowspan=5 style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|thumb|upright=0.4|center]]
 
|rowspan=5|<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn]
 
|rowspan=5|<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn]
−
|style="width: 25%; background-color:#deebf7"|[[Esophageal cancer]]
+
|style="background-color:#deebf7"|[[Esophageal cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Mesothelioma]]
+
|style="background-color:#deebf7"|[[Mesothelioma]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Non-small cell lung cancer]]
+
|style="background-color:#deebf7"|[[Non-small cell lung cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Small cell lung cancer]]
+
|style="background-color:#deebf7"|[[Small cell lung cancer]]
 
|-
 
|-
−
|style="width: 25%; background-color:#deebf7"|[[Thymoma]]
+
|style="background-color:#deebf7"|[[Thymoma]]
 
|-
 
|-
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Myeloproliferative Neoplasms'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Myeloproliferative Neoplasms'''

Revision as of 15:36, 4 October 2017

Please feel free to contact us with any questions or inquiries, at [email protected].

Editor-in-Chief

PeterYang.jpg
Peter C. Yang, MD
Boston, MA
Twitter: Hem_Onc

Deputy Editor

Warner Jeremy2 compact.jpg
Jeremy L. Warner, MD, MS
Nashville, TN
Twitter: Hemoncwarner
LinkedIn

Section Editors

Dermatologic Oncology
Bethbuchbinder.jpg
Elizabeth Buchbinder, MD
Boston, MA
LinkedIn 		Melanoma
Merkel cell carcinoma
Basal cell and squamous cell skin cancer
Cutaneous T-cell lymphoma
Gastrointestinal Oncology
Coming soon Neeta Venepalli, MD
Chicago, IL 		Anal cancer
Colon cancer
Esophageal cancer
Gastric cancer
Gastrointestinal stromal tumor (GIST)
Hepatobiliary cancer
Pancreatic cancer
Rectal cancer
Genitourinary Oncology
Coming soon Aymen Elfiky, MD, MSc, MBA
Boston, MA
LinkedIn 		Bladder cancer
Penile cancer
Prostate cancer
Renal cancer
Testicular cancer
Gynecologic Oncology
BrandonSeagle.jpg
Brandon L. Seagle, MD, MS
Chicago, IL 		Cervical cancer
Germ cell tumors
Ovarian cancer
Uterine cancer
Neuro-Oncology
SeemaNagpal.jpg
Seema Nagpal, MD
Palo Alto, CA 		Central nervous system (CNS) cancer
CNS leukemia
CNS lymphoma
Glioblastoma
Sarcoma
Coming soon James L. Chen, MD, MS
Columbus, OH
LinkedIn 		Ewing's sarcoma
Gastrointestinal stromal tumor
Osteosarcoma
Sarcoma (other types)
Thoracic Oncology
TravisOsterman.jpg
Travis Osterman, DO, MS
Nashville, TN
Twitter: TravisOsterman
LinkedIn 		Esophageal cancer
Mesothelioma
Non-small cell lung cancer
Small cell lung cancer
Thymoma
Myeloproliferative Neoplasms
Coming soon Sanjay R. Mohan, MD, MSCI
Nashville, TN 		Chronic myelogenous leukemia
Chronic myelomonocytic leukemia
Essential thrombocythemia
Hypereosinophilic syndrome
Myelofibrosis
Polycythemia vera
Systemic mastocytosis
Plasma Cell Dyscrasias
Headshot Cowan.jpg
Andrew J. Cowan, MD
Seattle, WA
LinkedIn 		Multiple myeloma
Light-chain (AL) amyloidosis
Plasma cell leukemia
Transplant
Arichall 400x400.jpg
Aric C. Hall, MD
Madison, WI
Twitter: AricHall1 		Stem cell mobilization
Allogeneic HSCT conditioning regimens
Autologous HSCT conditioning regimens
Graft versus host disease (GVHD)
Retrieved from "https://hemonc.org/w/index.php?title=Editorial_Board&oldid=17719"